Immunosuppressive properties of TNF blockers may increase risk of malignancy in children

Published August 2, 2010

Immunosuppressive properties of TNF blockers may increase risk of malignancy in children
The Food and Drug Administration (FDA) received reports of malignancies in children using tumor necrosis factor (TNF) blockers, raising concerns of an associated risk and prompting an investigation. Researchers from the FDA set out to identify all reports of malignancy in children using infliximab, etanercept, and adalimumab and their report is published in the August issue of Arthritis …
Read more on News-Medical-Net

Jazz “Liberates” Juarez
Under normal circumstances, an open-air concert would be no big deal. But normalcy flew out the door long ago in the Mexican border city of Ciudad Juarez. Nowadays, so many shootings and murders disturb the peace that any passage of…
Read more on New America Media